3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
29
Prostatic Neoplasms, Castration-Resistant
2
Prostate Cancer Metastatic
2
Metastatic Castration-resistant Prostate Cancer
2
Urogenital Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Prostatic Diseases
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Male Urogenital Diseases
1
Genital Neoplasms, Male
1
Fatigue
1
Depression
1
Advanced Prostate Cancer
1
Interventions
Gemcitabine
29
pembrolizumab
20
Cisplatin
20
Magnetic Resonance Spectroscopy
17
Specimen Handling
16
Mitomycin
10
enfortumab vedotin
9
durvalumab
9
Cystoscopy
9
avelumab
8
Nivolumab
8
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
6
atezolizumab
5
Transurethral Resection of Bladder
5
Radiotherapy
5
Mitozytrex
5
Docetaxel
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Platinum
4
Immunoglobulin G
4
Disulfides
4
1,2-diaminocyclohexaneplatinum II citrate
4
disitamab vedotin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Abiraterone Acetate
×
90 days
×
Clear all
No trials found.